Price Chart
Key Statistics
Previous Close
$271.77Day Range
52-Week Range
Avg Volume
66.0KDividend Yield
0.58%Expense Ratio
0.55%AUM
$2.89BShares Outstanding
6.2METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 83.50% |
| Denmark | 4.00% |
| Switzerland | 3.71% |
| Germany | 3.32% |
| Netherlands | 2.94% |
| Ireland | 2.45% |
| Other | 0.08% |
Fund Information
- Issuer
- First Trust
- Category
- Healthcare
- Types
- Biotech
- Inception Date
- Jun 19, 2006
- Exchange
- NYSE_ARCA
- Description
- The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index.
Similar ETFs
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund issued by First Trust that launched on Jun 19, 2006. It currently manages $2.89B in assets under management. The fund charges an expense ratio of 0.55%. The fund holds 30 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 40.8% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | HALO | Halozyme Therapeutics, Inc. | 4.93% | 1,199,043 | $145.7M |
| 2 | NTRA | Natera, Inc. | 4.64% | 338,462 | $137.0M |
| 3 | ILMN | Illumina, Inc. | 4.36% | 480,372 | $128.7M |
| 4 | GMAB | Genmab A/S (ADR) | 4.03% | 3,150,586 | $119.2M |
| 5 | RGEN | Repligen Corporation | 3.95% | 633,439 | $116.7M |
| 6 | ONC | BeOne Medicines Ltd. (ADR) | 3.87% | 305,884 | $114.4M |
| 7 | CORT | Corcept Therapeutics Inc. | 3.82% | 994,417 | $112.7M |
| 8 | NEO | NeoGenomics, Inc. | 3.78% | 6,475,340 | $111.7M |
| 9 | GILD | Gilead Sciences, Inc. | 3.75% | 703,742 | $110.7M |
| 10 | REGN | Regeneron Pharmaceuticals, Inc. | 3.71% | 137,493 | $109.5M |
| 11 | AMGN | Amgen Inc. | 3.69% | 251,429 | $109.1M |
| 12 | BIIB | Biogen Inc. | 3.65% | 458,787 | $108.0M |
| 13 | ADMA | ADMA Biologics, Inc. | 3.65% | 10,062,449 | $108.0M |
| 14 | EXEL | Exelixis, Inc. | 3.44% | 1,617,112 | $101.6M |
| 15 | VRTX | Vertex Pharmaceuticals Incorporated | 3.24% | 188,232 | $95.8M |
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | +0.55% | |
| 1W | +3.62% | |
| 1M | -0.48% | |
| 3M | +10.13% | |
| 6M | +33.62% | |
| YTD | +31.16% | |
| 1Y | +45.05% | |
| 3Y | +96.89% | |
| 5Y | +64.62% |
Moving Averages
$267.49
Above 20-Day MA$267.18
Above 50-Day MA$230.83
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$273.91
Current Price
$273.27
52-Week Low
$187.84
Current Yield
0.58%
Annual Dividend
$3.4263
Frequency
4x/year
Last Ex-Date
Dec 13, 2024
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 13, 2024 | $1.1726 | Dec 31, 2024 |
| Dec 30, 2021 | $2.2140 | Jan 10, 2022 |
| Sep 23, 2015 | $0.0200 | Sep 30, 2015 |
| Sep 23, 2015 | $0.0197 | Sep 30, 2015 |
| Jun 24, 2015 | $0.0650 | Jun 30, 2015 |
| Jun 24, 2015 | $0.0649 | Jun 30, 2015 |
| Mar 25, 2015 | $0.0480 | Mar 31, 2015 |
| Mar 25, 2015 | $0.0476 | Mar 31, 2015 |
| Dec 23, 2014 | $0.0524 | Dec 31, 2014 |
| Dec 23, 2014 | $0.0520 | Dec 31, 2014 |
| Jun 23, 2008 | $0.2700 | — |
| Jun 23, 2008 | $0.2697 | Jun 30, 2008 |
Dividend Payments Over Time
Category Comparison
| Metric | FBT | Healthcare(205 ETFs) | Biotech(41 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.55% | 0.64% | 0.86% |
| AUM | $2.89B | $868.4M | $1.84B |
| Dividend Yield | 0.58% | 4.50% | 1.97% |
| Avg Volume | 66.0K | 264.1K | 1.4M |
| Holdings | 30 | 145 | 63 |
| Performance | |||
| 1-Month Return | -0.48% | -1.96% | -1.63% |
| 6-Month Return | +31.84% | +10.01% | +21.82% |
| YTD Return | +31.93% | +11.25% | +20.41% |
| 1-Year Return | — | +7.17% | +16.65% |
Compare with Another ETF
Search for an ETF to compare with FBT:
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.